Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML)

Related Experiment Video

Updated: Jun 14, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K

Joanna Bao Ern Loh1, Patricia Walker1,2,3, Sharon Avery4

  • 1Department of Haematology, Alfred Hospital, Melbourne, Australia.

Leukemia & Lymphoma
|October 13, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.3K

Related Experiment Videos

Last Updated: Jun 14, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Articles linked to this work by shared authors, journal, and citation graph.

Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy.

Frontiers in immunology·2026

Toxicity-Related Treatment Cessation in Newly Diagnosed Multiple Myeloma-Risk Factors and Survival: An Analysis From the APAC and ANZ Myeloma and Related Diseases Registry.

European journal of haematology·2026

Estimating the Healthcare Cost of Infection-Related Hospitalisations in Multiple Myeloma.

PharmacoEconomics·2026

FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

Nature medicine·2026

Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP.

Molecular cell·2026

Spatial transcriptomics identifies a suppressive, T-cell-excluded tumor microenvironment in extramedullary myeloma.

Blood advances·2026

Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

Leukemia & lymphoma·2026

Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.

Leukemia & lymphoma·2026

Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.

Leukemia & lymphoma·2026

Zanubrutinib with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory non-germinal center B-cell lymphoma.

Leukemia & lymphoma·2026

Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.

Leukemia & lymphoma·2026

PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study.

Leukemia & lymphoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us